GlaxoSmithKline’s Nucala cuts severe asthma attacks in ‘reassuring’ interim real-world data
GlaxoSmithKline’s Nucala is facing an uphill climb in its battle for supremacy in severe asthma. On the hunt for a leg up, GSK is looking to real-world studies for a competitive advantage in Nucala’s sole indication—and it may have just scored one. After 12 months of use, Nucala cut severe eosinophilic asthma attacks by 69%… Read More »